
X
Sobi gets EU nod for Doptelet in rare blood disorder ITP
https://pharmaphorum.com/news/sobi-gets-eu-nod-for-doptelet-in-rare-blood-disorder-itp/
The FDA has accepted Novartis’ supplemental New Drug Application (sNDA) and granted Priority Review designation to Promacta (eltrombopag) in combination with standard immunosuppressive therapy (IST) for first-line treatment of severe aplastic anaemia (SAA), a rare and serious blood condition.
Drug could get new indication based on NIH research